E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Integrity of Energy Stores in Cat Papillary Muscle
TL;DR: The energy stores in papillary muscles, even of moderately large diameter, are intact for at least 3 hours while contracting at frequencies of 12/minute at 26°C, and energy stores of papillary muscle are even greater than those found in right ventricular muscle in vivo.
Journal ArticleDOI
The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial☆☆☆
Marc A. Pfeffer,Michael J. Domanski,Joel Verter,Mark Dunlap,Greg C. Flaker,Bernard J. Gersh,Judith Hsia,A. David Goldberg,Marian C. Limacher,Aldo P. Maggioni,Yves Rosenberg,Jean L. Rouleau,J. Wayne Warnica,Alan G. Wasserman,Eugene Braunwald +14 more
TL;DR: Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial is studied.
Journal ArticleDOI
2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians.
TL;DR: In 2004 the ACC/AHA guideline for the management of patients with STEMI was refocused and expanded, and here Robert Giugliano and Eugene Braunwald highlight the significant changes between the 1999 and 2004 versions that will most affect practicing clinicians.
Journal ArticleDOI
The effect of verapamil on myocardial ultrastructure during and following release of coronary artery occlusion.
TL;DR: Investigation of the effect of verapamil on the ultrastructure of myocardium during the early phase of ischemia and following coronary reperfusion in dogs found that the mean ischemic score, a semiquantitative index of ultrastructural damage, was significantly lower in verAPamil-treated dogs.
Journal ArticleDOI
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials.
Robert P. Giugliano,Carolyn H. McCabe,Rafael F. Sequeira,Martin J. Frey,Timothy D. Henry,Robert N. Piana,Jean Francois Tamby,Bradford K. Jensen,Sylvain B. Nicolas,Lisa K. Jennings,Robert J. Wise,Eugene Braunwald +11 more
TL;DR: Intravenous RPR 109891 is a potent, predictable, dose-related platelet inhibitor andInterrupted glycoprotein IIb/IIIa blockade may be associated with a higher risk of profound thrombocytopenia and deserves closer examination in future studies.